NasdaqGS:HSICHealthcare
Henry Schein (HSIC): Revisiting Valuation After Q3 2025 Earnings Beat and Upgraded Guidance
Henry Schein (HSIC) jumped about 11% after its Q3 2025 earnings beat expectations on both adjusted EPS and revenue, and management raised full year profit guidance alongside higher anticipated sales growth.
See our latest analysis for Henry Schein.
That earnings pop builds on a steady uptrend, with a roughly 14% 3 month share price return and about 11% 1 year total shareholder return suggesting momentum is quietly rebuilding after a softer multi year stretch.
If Henry Schein’s latest move has...